Group Leader: Marek Pruszyński, PhD, DSc

Dr Marek Pruszyński earned his Master’s degree in Chemistry from the Faculty of Biology and Chemistry at the University of Bialystok. In 2008, he completed his PhD in Chemistry at the Institute of Nuclear Chemistry and Technology (IChTJ) in Warsaw, where he later achieved his habilitation (DSc) in Chemistry in 2019. Since May 2021, Dr Pruszyński has been an Associate Professor at the National Centre for Nuclear Research (NCBJ) and leads the Novel Radiopharmaceuticals Group at the NOMATEN Centre of Excellence within the NCBJ. Throughout his career, he has been the Principal Investigator on several projects funded by prestigious Polish agencies, including the National Science Centre, the National Centre for Research and Development, and the Polish National Agency for Academic Exchange. Additionally, he has been awarded scholarships from the Polish-US Fulbright Commission (2006) and the International Atomic Energy Agency (2007).

Dr Pruszyński’s research focuses on the design and synthesis of molecular radiopharmaceuticals and their preclinical evaluation for diagnostic and therapeutic applications. His work significantly contributes to understanding how radiolabelling procedures, involving chelators or prosthetic groups, impact the biological activity of targeting vectors.

Scopus Author ID: 58371125400

Web of Science ResearcherID: DYN-7209-2022

ORCID: 0000-0001-8835-2462